Rigel Pharmaceuticals Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 284.09, 319.62, 362.21, 360.92, 392.17 ], "ebit_estimate": [ 87.05, 97.12, 107.84, 103.4, 118.87 ], "ebitda_estimate": [ 86.1, 124.3, 152.1, null, null ], "net_income_estimate": [ 71.99, 77.17, 86.41, 83.36, 96.38 ], "per_share_eps_estimate": [ 3.57, 3.35, 3.73, 4.05, 4.08 ], "eps_nri_estimate": [ 3.57, 3.35, 3.73, 4.05, 4.08 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null ], "pretax_income_estimate": [ 89.15, 100.57, 111.81, 104.7, 120.68 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ 0.03, 0.32, 0.32, null, null ], "gross_margin_estimate": [ 92, 92, 92, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null ], "pettm_estimate": [ 11.94, 12.7, 11.41, 10.51, 10.43 ], "long_term_growth_rate_mean": -15.76, "long_term_revenue_growth_rate_mean": "7.69", "future_per_share_eps_estimate_growth": -39.48, "future_eps_nri_estimate_growth": -15.76, "future_revenue_estimate_growth": 7.69, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -0.43, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 68.91, 74.88, 81.4, 70.11, 74.66, 78.08, 84.67 ], "ebit_estimate": [ 20.21, 24.12, 27.33, 18.86, 21.17, 20.11, 23.26 ], "ebitda_estimate": [ 22.9, 24.8, 26.7, null, null, null, null ], "net_income_estimate": [ 17.98, 20.55, 22.56, 15.49, 17.51, 16.83, 19.6 ], "per_share_eps_estimate": [ 0.91, 1.05, 1.16, 0.75, 0.84, 0.79, 0.91 ], "eps_nri_estimate": [ 0.91, 1.05, 1.16, 0.75, 0.84, 0.79, 0.91 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ 23.19, 24.58, 24.81, 21.95, 24.61, 23.94, 27.46 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ -0.52, 0.32, 0.19, null, null, null, null ], "gross_margin_estimate": [ 92, 92, 91, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 11.02, 11.21, 12.04, 12.93, null, null, null ], "long_term_growth_rate_mean": -15.76, "long_term_revenue_growth_rate_mean": "7.69", "future_per_share_eps_estimate_growth": -39.48, "future_eps_nri_estimate_growth": -15.76, "future_revenue_estimate_growth": 7.69, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -0.43, "future_operating_cash_flow_per_share_estimate_growth": null }